- Cardiff Oncology press release ( NASDAQ: CRDF ): FY GAAP EPS of -$0.89 beats by $0.05 .
- Revenue of $0.39M (+8.3% Y/Y) beats by $0.12M .
For further details see:
Cardiff Oncology GAAP EPS of -$0.89 beats by $0.05, revenue of $0.39M beats by $0.12MFor further details see:
Cardiff Oncology GAAP EPS of -$0.89 beats by $0.05, revenue of $0.39M beats by $0.12MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR dem...